Talecris

Grifols surged 5.3% in Madrid after the Spanish maker of blood-plasma products said its purchase of Talecris Biotherapeutics Holdings has won tentative U.S. antitrust approval.

European Stocks Rise After Bin Laden's Death Aude Lagorce 2011

Talecris, based in Research Triangle Park, N.C., was formed in 2005 when Cerberus, along with Boston-based private-equity firm Ampersand Ventures, paid about $450 million for the blood-plasma unit of German drug company

Grifols to Buy Talecris for $3 Billion 2010

This deal is likely to garner less antitrust scrutiny, given that Grifols has little presence in the U.S., while Talecris doesn't have much abroad.

Grifols to Buy Talecris for $3 Billion 2010

This deal is likely to garner less antitrust scrutiny, given that Grifols has little presence in the U.S., while Talecris doesn't have much abroad.

Spanish Firm Grifols to Acquire Talecris 2010

Federal Trade Commission will block the takeover on antitrust grounds, as it did with Australian group CSL's bid for Talecris last year.

Cerberus's Red-Blooded Returns 2010

The deal values Talecris at 10.2 times forecast 2010 earnings before interest, taxes, depreciation and amortization, compared with a sector average multiple of 8.5 times.

Cerberus's Red-Blooded Returns 2010

Cerberus Capital Management will make more than 20 times its original investment in Talecris, which it has agreed to sell to Spanish group

Cerberus's Red-Blooded Returns 2010

Talecris shares, which were trading near their 52-week low, jumped 26% to $20 in recent trading.

Spanish Firm Grifols to Acquire Talecris 2010

Ltd., an Australian biotechnology company, announced a deal to buy Talecris for $3.1 billion in cash.

Grifols to Buy Talecris for $3 Billion 2010

Even though it is barely bigger than Talecris as measured by market value, Grifols was able to cobble together the cash needed for the deal from a group of banks including

Spanish Firm Grifols to Acquire Talecris 2010